Gynecologic Oncology

Adria Suarez Mora, MD, second-year fellow at UPMC Magee-Womens Hospital, discusses how sequential sampling of intraperitoneal fluid during chemotherapy help better define the immunogenic effects of the treatment.

Kathleen G. Essel, MD, gynecologic oncology fellow at the University of Oklahoma Health Science Center with the Stephenson Cancer Center, discusses the benefits of using quantitative computed tomography image feature analysis to predict response to immune checkpoint inhibitors in patients with gynecologic cancers.

Targeted therapy is effectively established as an option for patients with ovarian cancers. However, beyond PARP inhibition in the BRCA-mutated or homologous recombination deficient population, questions remain about how to best treat these patients.

The prognosis for women with recurrent or metastatic cervical cancer after treatment failure is notoriously poor, but immunotherapy agents may offer longer survival for this population.

Genomic testing to guide treatment decisions for women with ovarian cancer is in its early days. However, as more platforms become commercially available, physicians will need to understand the similarities and differences between tests.

Eleftheria Kalogera, MD, MSc, instructor in Obstetrics and Gynecology, fellow in Gynecologic Oncology, in the department of Obstetrics and Gynecology, at Mayo Clinic College of Medicine, discusses the controversial topic of bowel preparation following minimally invasive or open hysterectomies.

Panagiotis A. Konstantinopoulos, MD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the disappointing results of the JAVELIN 200 trial in ovarian cancer.

Suzanne George, MD, highlights the available therapies for patients with uterine sarcomas and what novel options are on the horizon.

Nearly 1 IN 5 women who undergoes ovarian cancer surgery is readmitted for complications, but a web-based app may improve patient monitoring so complications and adverse events can be addressed quickly by the patient’s care team.

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the use of immunotherapy in patients with recurrent ovarian cancer.

Huma Q. Rana, MD, clinical director, Cancer Genetics and Prevention, instructor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses genetic testing guidelines for patients with ovarian cancer.

Joyce F. Liu, MD, MPH, assistant professor of medicine and director of clinical research for gynecologic oncology at Dana-Farber Cancer Institute, discusses the use of bevacizumab (Avastin) in the treatment of patients with newly diagnosed advanced ovarian cancer.

The presence of specific subtypes of HPV, namely HPV-16 and -18, were found to be associated with a higher risk of developing high-grade cervical intraepithelial neoplasia in women under the age of 30.

The impact of subsequent lines of treatment on trial outcomes can be substantial, seriously challenging the relevance of OS as an objectively meaningful study endpoint.

Diana P. English, MD, a gynecologic oncologist at Stanford Hospital and Clinics, discusses the development of the antibody drug conjugate (ADC) mirvetuximab soravtansine in ovarian cancer.

Peter Levonian, MS, senior genetic counselor, Stanford Medicine, discusses the potential risks of genetic testing in ovarian cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended to expand the approval of single-agent rucaparib as a maintenance therapy in adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

Since the introduction of platinum agents in ovarian cancer, it is reasonable to suggest there have been only limited changes in the basic paradigm of ovarian cancer management over the past several decades.

Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses safety signals with the combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) in endometrial cancer.

Oliver Dorigo, MD, PhD, discusses the promise of immunotherapy in ovarian cancer.

Elisabeth Diver, MD, discusses ongoing advances with PARP inhibitors in ovarian cancer.

Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination approaches garnering interest in endometrial cancer.

Trung Nguyen, DO, MBA, clinical assistant professor, Obstetrics and Gynecology, Gynecologic Oncology, Stanford Medicine, discusses treatment approaches for patients with advanced ovarian cancer.

Oliver Dorigo, MD, PhD, associate professor of Obstetrics and Gynecology, Stanford University Medical Center, Stanford Medicine, discusses the use of immunotherapy in the treatment of patients with ovarian cancer.

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses the next steps with cemiplimab (Libtayo) in the treatment landscape of cervical cancer.